WO2000025138A3 - Methods of diagnosing or prognosing alzheimer's disease - Google Patents

Methods of diagnosing or prognosing alzheimer's disease Download PDF

Info

Publication number
WO2000025138A3
WO2000025138A3 PCT/EP1999/008023 EP9908023W WO0025138A3 WO 2000025138 A3 WO2000025138 A3 WO 2000025138A3 EP 9908023 W EP9908023 W EP 9908023W WO 0025138 A3 WO0025138 A3 WO 0025138A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
subject
diagnosing
activity
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/008023
Other languages
French (fr)
Other versions
WO2000025138A2 (en
Inventor
Roger Nitsch
John Growdon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP99101377A external-priority patent/EP1024364A1/en
Application filed by Individual filed Critical Individual
Priority to EP99971091A priority Critical patent/EP1123509B1/en
Priority to DE69922987T priority patent/DE69922987T2/en
Priority to AU11533/00A priority patent/AU1153300A/en
Priority to AT99971091T priority patent/ATE286253T1/en
Priority to JP2000578661A priority patent/JP2002531063A/en
Publication of WO2000025138A2 publication Critical patent/WO2000025138A2/en
Publication of WO2000025138A3 publication Critical patent/WO2000025138A3/en
Anticipated expiration legal-status Critical
Priority to US11/979,234 priority patent/US20090023145A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

A method for diagnosing or prognosing Alzheimer's disease in a subject, or determining whether a subject is at increased risk of developing Alzheimer's disease, comprising: determining a level, or an activity, or both said level and said activity, of transcription product and/or a translation product of (i) a cystatin C gene or (ii) a polymorphic variant of a cystatin C gene in a sample from said subject; and comparing said level, or said activity, or both said level and said activity, of said transcription product and/or said translation product to a reference value representing a known disease or health status, thereby diagnosing or prognosing Alzheimer's disease in said subject, or determining whether said subject is at increased risk of developing Alzheimer's disease.
PCT/EP1999/008023 1998-10-23 1999-10-22 Methods of diagnosing or prognosing alzheimer's disease Ceased WO2000025138A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP99971091A EP1123509B1 (en) 1998-10-23 1999-10-22 Methods of diagnosing or prognosing alzheimer's disease
DE69922987T DE69922987T2 (en) 1998-10-23 1999-10-22 METHODS OF DIAGNOSIS OR FORECAST OF ALZHEIMER'S DISEASE
AU11533/00A AU1153300A (en) 1998-10-23 1999-10-22 Methods of diagnosing or prognosing alzheimer's disease
AT99971091T ATE286253T1 (en) 1998-10-23 1999-10-22 METHODS FOR DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE
JP2000578661A JP2002531063A (en) 1998-10-23 1999-10-22 Methods for diagnosing or prognosing Alzheimer's disease
US11/979,234 US20090023145A1 (en) 1998-10-23 2007-10-31 Methods of diagnosing or prognosing Alzheimer's disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10545898P 1998-10-23 1998-10-23
US60/105,458 1998-10-23
US10743498P 1998-11-06 1998-11-06
US60/107,434 1998-11-06
EP99101377.2 1999-01-26
EP99101377A EP1024364A1 (en) 1999-01-26 1999-01-26 Methods of diagnosing or prognosing Alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/979,234 Continuation US20090023145A1 (en) 1998-10-23 2007-10-31 Methods of diagnosing or prognosing Alzheimer's disease

Publications (2)

Publication Number Publication Date
WO2000025138A2 WO2000025138A2 (en) 2000-05-04
WO2000025138A3 true WO2000025138A3 (en) 2000-08-24

Family

ID=27239924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008023 Ceased WO2000025138A2 (en) 1998-10-23 1999-10-22 Methods of diagnosing or prognosing alzheimer's disease

Country Status (8)

Country Link
US (1) US20090023145A1 (en)
EP (1) EP1123509B1 (en)
JP (1) JP2002531063A (en)
AT (1) ATE286253T1 (en)
AU (1) AU1153300A (en)
DE (1) DE69922987T2 (en)
ES (1) ES2235550T3 (en)
WO (1) WO2000025138A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986989B2 (en) 1996-07-29 2006-01-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012123D0 (en) * 2000-05-20 2000-07-12 Univ Dundee Alzheimer's disease assay
US20020025527A1 (en) * 2000-07-03 2002-02-28 Fiona Crawford Methods and assays for diagnosing alzheimer's disease
CA2745998C (en) * 2002-08-23 2013-11-26 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
EP1394549A1 (en) * 2002-08-23 2004-03-03 Bayer HealthCare AG Biomarkers for diagnosing Alzheimer's disease
WO2004042390A2 (en) * 2002-11-08 2004-05-21 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b)
EP1426767A1 (en) * 2002-12-04 2004-06-09 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4c (PDE4C)
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
EP2154969B1 (en) * 2007-05-16 2015-11-18 The Brigham and Women's Hospital, Inc. Treatment of synucleinopathies
KR102572009B1 (en) * 2020-10-21 2023-08-29 순천향대학교 산학협력단 Biomarker composition for diagnosing neurodegenerative diseases comprising Cystatin C, and uses thereof
CN115612728A (en) * 2021-07-16 2023-01-17 深圳先进技术研究院 Neurodegenerative disease marker and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2711201A1 (en) * 1977-03-15 1978-09-21 Kluthe Reinhold Kidney function testing device for home use - indicates urea content of saliva or urine by discolouration along length of probe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2711201A1 (en) * 1977-03-15 1978-09-21 Kluthe Reinhold Kidney function testing device for home use - indicates urea content of saliva or urine by discolouration along length of probe

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FUJIHARA S ET AL: "CEREBRAL AMYLOID ANGIOPATHY WITH THE DEPOSITION OF CYSTATIN C GAMMA-TRACE AND BETA-PROTEIN.", KAMEYAMA, M. (ED.). INTERNATIONAL CONGRESS SERIES, NO. 999. BETA-AMYLOID PRECURSOR PROTEINS AND NEUROTRANSMITTER FUNCTION;EIGHTH WORKSHOP ON NEUROTRANSMITTERS AND DISEASES, TOKYO, JAPAN, JUNE 1, 1991. VII+107P. ELSEVIER SCIENCE PUBLISHERS B.V.: AMSTE, XP002110418 *
LÖFBERG, H. ET AL.: "The Cerebrospinal Fluid and Plasma Concentrations of Gamma-Trace and Beta-2-Microglobulin at Various Ages and in Neurological Disorders", JOURNAL OF NEUROLOGY, vol. 223, no. 3, 1980, pages 159 - 170, XP002110417 *
MARUYAMA, KEIKO ET AL.: "Immunohistochemical Characterization of Cerebrovascular Amyloid in 46 Autopsied Cases Using Antibodies to beta-Protein and Cystatin C", STROKE, vol. 21, no. 3, March 1990 (1990-03-01), pages 397 - 403, XP000869870 *
PETURSDOTTIR I ET AL: "ESTIMATION OF CYSTATIN C IN DIFFERENT HUMAN EXTRACELLULAR FLUIDS.", FIRST SYMPOSIUM ON HEREDITARY CENTRAL NERVOUS SYSTEM AMYLOID ANGIOPATHY, REYKJAVIK, ICELAND, SEPT. 2-3, 1985. ACTA NEUROL SCAND. (1986) 73 (3), 318., XP002110416 *
VINTERS, H.V. ET AL.: "Immunoreactive A4 and Gamma-trace Peptide Colocalization in Amyloidotic Arteriolar Lesions in Brains of Patients with Alzheimer's Disease", THE AMERICAN JOURNAL OF PATHOLOGY, vol. 137, no. 2, August 1990 (1990-08-01), pages 233 - 240, XP000866515 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6986989B2 (en) 1996-07-29 2006-01-17 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor

Also Published As

Publication number Publication date
EP1123509B1 (en) 2004-12-29
ATE286253T1 (en) 2005-01-15
DE69922987T2 (en) 2006-05-04
DE69922987D1 (en) 2005-02-03
US20090023145A1 (en) 2009-01-22
WO2000025138A2 (en) 2000-05-04
ES2235550T3 (en) 2005-07-01
AU1153300A (en) 2000-05-15
JP2002531063A (en) 2002-09-24
EP1123509A2 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
WO2000004187A3 (en) Methods and kits for diagnosing and determination of the predisposition of diseases
WO2000018954A3 (en) Use of pex in the treatment of metabolic bone diseases
WO2000025138A3 (en) Methods of diagnosing or prognosing alzheimer's disease
WO2004020968A3 (en) Mutations in nod2 are associated with fibrostenosing disease in patients with crohn’s disease
WO1997012992A3 (en) Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
EP1503213A3 (en) Detection and determination of the stages of coronary disease
WO1998027226B1 (en) Method for determining the prognosis of a patient with a neurological disease
WO1999052942A3 (en) Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
WO2001001218A3 (en) Methods for obtaining and using haplotype data
EP1521083A3 (en) Method for diagnosing and distinguishing stroke
WO2001016364A3 (en) Methods of diagnosing or prognosticating age-related macular degeneration
WO2004046729A3 (en) Bodily fluid markers of tissue hypoxia
AUPS293002A0 (en) Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
CA2267155A1 (en) Detecting genetic predisposition to sight-threatening diabetic retinopathy
Schmidt et al. The natural course of MRI white matter hyperintensities
WO2001020533A3 (en) Creation of a database of biochemical data and methods of use
EP1132483A3 (en) Method for diagnosing schizophrenia using objective indices
WO2001004349A3 (en) Method for the diagnosis or the prognosis of alzheimer disease therapeutical composition for preventing or treating alzheimer disease
ATE375404T1 (en) METHOD FOR COLLECTING DATA FOR THE PRESYMPTOMATIC OR PRENATAL DIAGNOSIS OF TYPE 1 NEUROFIBROMATOSIS
EP0757105A3 (en) Serum markers as predictors of adult respiratory distress syndrome
NZ335335A (en) Identification of clk-1 and shows that clk-1 gene complements the clk-1 phenotype and restores normal longevity
AU4753900A (en) Methods of diagnosing or treating alzheimer's disease
WO1991012339A3 (en) Allelic association of the human dopamine (d2) receptor gene in compulsive disorders such as alcoholism
AU2904197A (en) Diagnostic method and apparatus based on polymorphism in an IL-6 gene
AU4753800A (en) Methods of diagnosing or treating depression

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 2000 11533

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999971091

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 578661

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09806509

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999971091

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1999971091

Country of ref document: EP